Current approaches for the treatment of cognitive deficits in CNS disease.
Hudkins
Robert L
RL
D014150:Antipsychotic Agents / Q000494:pharmacology*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000503:physiopathology; D055808:Drug Discovery; D005998:Glycine / Q000037:antagonists & inhibitors; D054828:Histamine H3 Antagonists / Q000494:pharmacology*; D006801:Humans; D018733:Nicotinic Antagonists / Q000494:pharmacology*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D018100:Receptors, Histamine H3 / Q000378:metabolism; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism
D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D054828:Histamine H3 Antagonists; D018733:Nicotinic Antagonists; D018100:Receptors, Histamine H3; D018094:Receptors, Metabotropic Glutamate; D011978:Receptors, Nicotinic; D011985:Receptors, Serotonin; C097216:serotonin 6 receptor; D010727:Phosphoric Diester Hydrolases; D005998:Glycine